Blood and Tumor Samples to Study Tumor DNA in Soft Tissue Sarcoma
Collects blood and tumor samples from adults with soft tissue sarcoma.
Plain-language title generated from the registry record
Registry title: Circulating Tumor DNA in Soft Tissue Sarcoma
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT03818412
- Record updated
- 23 June 2026
- Original description
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.Read full original descriptionShow less
Circulating Tumor DNA Detection in Soft Tissue Sarcoma (DNA-TSAR)
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.
Inclusion: Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma; Patients must have archival tissue from the diagnostic biopsy available; Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist; Age 18 years or older; Eastern Cooperative Group (ECOG) performance status ≤ 2; Ability to understand and willing to sign a written informed consent document and comply with study requirements.
Exclusion: Patients with planned neo-adjuvant chemotherapy; Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix; Patients with regional nodal disease or unequivocal metastases; Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; Patients with benign histology.